Cancer

Anavex Life Sciences Reports Fiscal 2023 Second Quarter Financial Results

Newly available preliminary efficacy results of surrogate biomarkers from the ANAVEX®2-73-AD-004 study; allowing initiation of discussions with regulatory agencies for…

1 year ago

Sensei Biotherapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights

- Investigational New Drug (IND) application for SNS-101 cleared by U.S. Food and Drug Administration (FDA) with first patient dose…

1 year ago

Be The Match Champions Raise Over $420,000 at 2023 New York Gala to Save More Lives Through Blood Stem Cell Transplants

NY Times Bestselling Author and Transplant Recipient Suleika Jaouad Honored with Inaugural INSPIRE Award and Amazon Web Services Awarded for…

1 year ago

Prelude Therapeutics Announces First Quarter 2023 Financial Results and Operations Update

Eight abstracts presented at AACR 2023 demonstrate progress of the pipeline Cash runway unchanged, supporting operations into the fourth quarter…

1 year ago

CorMedix Inc. To Report First Quarter 2023 Financial Results and Provide a Corporate Update on May 15, 2023

BERKELEY HEIGHTS, N.J., May 08, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and…

1 year ago

Recursion Provides Business Updates and Reports First Quarter 2023 Financial Results

Recursion's Pipeline Recursion's internal pipeline as of Q1 2023Entered into agreements to acquire Cyclica and Valence to bolster digital chemistry…

1 year ago

Adagene Achieves $3 Million Milestone in Collaboration with Exelixis for Successful Nomination of Second SAFEbody® Novel Masked Antibody-Drug Conjugate

SAN DIEGO and SUZHOU, China, May 04, 2023 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology…

1 year ago

Eterna Therapeutics to Deliver Eight Presentations at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting

Eterna to present data on iPS cell-derived multi-cell-type therapeutic strategy for solid-tumor targeting, nucleic-acid delivery, and targeted gene insertion CAMBRIDGE,…

1 year ago

IMUNON to Hold First Quarter 2023 Financial Results and Business Update Conference Call on Thursday, May 11, 2023

LAWRENCEVILLE, N.J., May 04, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated…

1 year ago

Compass Therapeutics Reports First Quarter Financial Results and Provides Corporate Update

Initiated patient enrollment in a U.S. Phase 2/3 study of CTX-009 (DLL4 /VEGF-A bispecific antibody) in patients with advanced biliary…

1 year ago